Coronary heart disease kills more than twice as many women in the UK as breast cancer each year. Yet cardiovascular disease in women remains persistently under-recognised — by patients, by clinicians, and by the public health messaging that still frames heart attacks as a predominantly male event.
The British Heart Foundation reports that women in the UK wait an average of 11 minutes longer than men to receive emergency treatment after calling 999 with a heart attack. Women are less likely to receive guideline-recommended treatments, less likely to attend cardiac rehabilitation, and more likely to die within a year of a first heart attack.
The renewed Women's Health Strategy, announced on 15 April 2026, commits to addressing the health conditions that most affect women's lives. Cardiovascular disease — often overlooked in favour of reproductive and cancer-focused women's health agendas — belongs at the centre of that conversation.
How women's cardiovascular risk differs
Women share the same classical risk factors as men — hypertension, smoking, diabetes, dyslipidaemia, obesity, physical inactivity, family history — but several additional factors are unique to or more significant in women:
| Risk factor | Relevance to women |
|---|---|
| Pre-eclampsia | History of pre-eclampsia doubles lifetime cardiovascular risk; NICE recommends annual cardiovascular review |
| Gestational diabetes | Increases risk of type 2 diabetes and subsequent CVD by 7-fold |
| PCOS | Associated with insulin resistance, dyslipidaemia and increased CVD risk |
| Premature menopause (before age 40) | Loss of oestrogen's cardioprotective effect earlier; associated with increased CVD risk |
| Autoimmune conditions (RA, SLE) | More common in women; systemic inflammation accelerates atherosclerosis |
| Depression and anxiety | More prevalent in women; independently associated with CVD |
| Breast cancer treatment | Anthracycline chemotherapy and left-sided radiotherapy are cardiotoxic |
These factors mean that a standard QRISK3 cardiovascular risk assessment may underestimate true risk in women with pregnancy complications or autoimmune conditions.
Pharmacy's role in cardiovascular screening
Community pharmacies are one of the most accessible healthcare settings for cardiovascular risk identification. Key touchpoints include:
NHS blood pressure checks
Many pharmacies offer free NHS Hypertension Case-Finding Service checks. This is a direct route to identifying undiagnosed hypertension — the single most important modifiable risk factor for cardiovascular disease. Women attending for other pharmacy services (prescription collection, menopause products, contraception) can be offered a blood pressure check opportunistically.
A reading of ≥140/90 mmHg triggers referral for ambulatory blood pressure monitoring (ABPM) via the GP. Pharmacy teams should ensure that women with a history of pre-eclampsia or gestational hypertension are aware of their elevated long-term risk and offered regular monitoring.
Statin dispensing and adherence
Statins are underused in women relative to men. A 2023 analysis in The Lancet found that women were less likely to be prescribed statins for primary prevention despite equivalent cardiovascular risk scores. When dispensing statins to women, pharmacy teams should:
- Reinforce that statins are evidence-based for women as well as men
- Address common concerns about side effects (muscle pain is reported more frequently in women)
- Note that statins are contraindicated in pregnancy — women of childbearing age on statins should be counselled about effective contraception
Smoking cessation
Smoking increases cardiovascular risk in women more than in men, relative to non-smokers of the same sex. Pharmacy smoking cessation services, including varenicline and NRT supply, are a direct intervention against women's cardiovascular mortality. The combined effect of smoking and oral contraceptive pill use dramatically increases the risk of venous thromboembolism and stroke, particularly in women over 35.
Weight management
Community pharmacy weight management services have expanded with the availability of GLP-1 receptor agonists. For women with central obesity — an independent cardiovascular risk factor — pharmacy-based interventions offer an accessible entry point to risk reduction.
Symptoms women may present with
Pharmacy teams should be aware that women experiencing a cardiac event may present differently from men:
| Classic (textbook) presentation | More common in women |
|---|---|
| Crushing central chest pain radiating to left arm | Jaw, neck or back pain |
| Sudden onset | Gradual onset, building over hours |
| Sweating, pallor | Nausea, breathlessness, fatigue |
| Clutching chest | "Something doesn't feel right" |
A woman describing persistent jaw pain, unusual breathlessness, or nausea with back pain should not be reassured with antacids or analgesics. If there is any suspicion of an acute cardiac event, advise calling 999 immediately.
The menopause transition
The menopause is a critical inflection point for cardiovascular risk. Declining oestrogen levels are associated with:
- Rising LDL cholesterol and falling HDL cholesterol
- Increased central adiposity
- Rising blood pressure
- Insulin resistance
This is not an argument for HRT as cardiovascular protection — the evidence does not support prescribing HRT for that purpose. But it does mean that the perimenopausal years are the right time for cardiovascular risk assessment, and pharmacy teams dispensing HRT or menopause-related products should consider whether a cardiovascular review has been done.
Data context
PharmSee tracks 1,742 active pharmacy vacancies across England. Cardiovascular risk management is a core pharmacy competency spanning dispensing, OTC advice, blood pressure monitoring and smoking cessation. For pharmacies offering NHS blood pressure checks near you, use PharmSee's pharmacy finder.
For salary and career data in pharmacy roles that include cardiovascular screening, see the PharmSee salary guide.
Caveats
Cardiovascular mortality data is from the British Heart Foundation and Office for National Statistics. The 11-minute treatment delay figure is from the BHF's published analysis of ambulance response data. Statin prescribing gender gap data is from published Lancet analyses. PharmSee does not track pharmacy service provision for cardiovascular screening.
Sources: British Heart Foundation, ONS Mortality Statistics, NICE CVD Risk Assessment Guidelines, The Lancet, NICE NG133, PharmSee vacancy database (April 2026), BBC News (15 April 2026).